Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2018 1
2020 2
2023 2
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

5 results

Results by year

Filters applied: . Clear all
Page 1
Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants (most commonly F508del).
Southern KW, Murphy J, Sinha IP, Nevitt SJ. Southern KW, et al. Cochrane Database Syst Rev. 2020 Dec 17;12(12):CD010966. doi: 10.1002/14651858.CD010966.pub3. Cochrane Database Syst Rev. 2020. PMID: 33331662 Free PMC article. Updated.
Lumacaftor-ivacaftor was associated with an increase in early transient shortness of breath and longer-term increases in blood pressure (not observed for tezacaftor-ivacaftor). ...In this population, lumacaftor-ivacaftor had an important impact on respiratory function with …
Lumacaftor-ivacaftor was associated with an increase in early transient shortness of breath and longer-term increases in blood pressu …
Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants (most commonly F508del).
Heneghan M, Southern KW, Murphy J, Sinha IP, Nevitt SJ. Heneghan M, et al. Cochrane Database Syst Rev. 2023 Nov 20;11(11):CD010966. doi: 10.1002/14651858.CD010966.pub4. Cochrane Database Syst Rev. 2023. PMID: 37983082 Review.
Lumacaftor-ivacaftor was associated with an increase in early transient shortness of breath and longer-term increases in blood pressure (not observed for tezacaftor-ivacaftor). ...In this population, lumacaftor-ivacaftor had an important impact on respiratory function with …
Lumacaftor-ivacaftor was associated with an increase in early transient shortness of breath and longer-term increases in blood pressu …
EMS Field Identification Of Chronic Obstructive Pulmonary Disease (COPD).
McLendon K, Edemekong PF. McLendon K, et al. 2023 Aug 14. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan–. 2023 Aug 14. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan–. PMID: 29630282 Free Books & Documents.
Most often, the reported complaint will be respiratory, for example, shortness of breath, difficulty breathing, dyspnea, or a cough. Additionally, it may also be complaints of chest pain, fever, or other broad complaints. ...
Most often, the reported complaint will be respiratory, for example, shortness of breath, difficulty breathing, dyspnea, or a cough. …
Correctors (specific therapies for class II CFTR mutations) for cystic fibrosis.
Southern KW, Patel S, Sinha IP, Nevitt SJ. Southern KW, et al. Cochrane Database Syst Rev. 2018 Aug 2;8(8):CD010966. doi: 10.1002/14651858.CD010966.pub2. Cochrane Database Syst Rev. 2018. PMID: 30070364 Free PMC article. Updated. Review.
Lumacaftor-ivacaftor is associated with an increase in early transient shortness of breath and longer-term increases in blood pressure (high-quality evidence). ...In this age group, lumacaftor-ivacaftor had an important impact on respiratory function with no apparent immed …
Lumacaftor-ivacaftor is associated with an increase in early transient shortness of breath and longer-term increases in blood pressur …
COVID-19 and clinical mimics. Correct diagnosis is the key to appropriate therapy.
Sahu KK, Mishra AK, Martin K, Chastain I. Sahu KK, et al. Monaldi Arch Chest Dis. 2020 May 6;90(2). doi: 10.4081/monaldi.2020.1327. Monaldi Arch Chest Dis. 2020. PMID: 32380803 Free article.
We hereby discuss the challenges faced while approaching any case of shortness of breath, or other common upper respiratory symptoms during the current COVID-19 pandemic era....
We hereby discuss the challenges faced while approaching any case of shortness of breath, or other common upper respiratory symptoms …